- Home
- GBIO vs MCRB Comparison
GBIO vs MCRB Comparison
Compare GBIO & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- MCRB
- Stock Information
- Founded
- GBIO 2016
- MCRB 2010
- Country
- GBIO United States
- MCRB United States
- Employees
- GBIO N/A
- MCRB N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- GBIO Health Care
- MCRB Health Care
- Exchange
- GBIO Nasdaq
- MCRB Nasdaq
- Market Cap
- GBIO 29.5M
- MCRB 165.3M
- IPO Year
- GBIO 2020
- MCRB 2015
- Fundamental
- Price
- GBIO $5.87
- MCRB $17.37
- Analyst Decision
- GBIO Buy
- MCRB Hold
- Analyst Count
- GBIO 4
- MCRB 4
- Target Price
- GBIO $10.67
- MCRB $73.67
- AVG Volume (30 Days)
- GBIO 76.7K
- MCRB 247.1K
- Earning Date
- GBIO 11-05-2025
- MCRB 11-12-2025
- Dividend Yield
- GBIO N/A
- MCRB N/A
- EPS Growth
- GBIO N/A
- MCRB N/A
- EPS
- GBIO N/A
- MCRB 10.22
- Revenue
- GBIO $21,230,000.00
- MCRB N/A
- Revenue This Year
- GBIO N/A
- MCRB N/A
- Revenue Next Year
- GBIO N/A
- MCRB N/A
- P/E Ratio
- GBIO N/A
- MCRB $1.71
- Revenue Growth
- GBIO 61.15
- MCRB N/A
- 52 Week Low
- GBIO $3.00
- MCRB $6.53
- 52 Week High
- GBIO $29.10
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- GBIO 51.33
- MCRB 50.10
- Support Level
- GBIO $5.51
- MCRB $14.22
- Resistance Level
- GBIO $6.04
- MCRB $24.67
- Average True Range (ATR)
- GBIO 0.32
- MCRB 2.01
- MACD
- GBIO -0.09
- MCRB -0.48
- Stochastic Oscillator
- GBIO 30.93
- MCRB 30.16
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.